Evidence regarding the association between oral environment and the inflammatory bowel disease (IBD), including ulcerative colitis (UC), exists. However, evidence regarding the association between oral health parameters and disease activity of UC is limited. This study aimed to evaluate the association between remaining tooth number and toothbrushing frequency and mucosal healing (MH) in Japanese UC patients. The study included 275 patients with UC. Information on lifestyle and oral health parameters was collected via self-administered questionnaires. The definition of MH was based on the Mayo endoscopic subscore (MES) of 0. The prevalence of MH in this cohort was 24.7
BACKGROUND:Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline resectable (BR) classification combined with the barcelona clinic liver cancer (BCLC) staging system to identify patients most likely to benefit from conversion following atezolizumab plus bevacizumab (ATZ/BEV) therapy. METHODS:In this multicenter retrospective study, 532 patients with unresectable HCC treated with ATZ/BEV were categorized using the BR classification and stratified according to the BCLC stage. We evaluated objective response rate (ORR), conversion rate, and overall survival (OS) and carried out multivariate logistic regression analysis to identify predictors of conversion. RESULTS:Conversion therapy was performed in 5.9% of patients. Among those with BCLC-C HCC, the conversion rate was significantly higher in BR1 HCC than in BR2 HCC (15.2% vs. 2.0% and p < 0.01), and BR1 status was independently associated with conversion (odds ratio 7.0). Patients with BCLC-C/BR1 staging showed the highest ORR (45.0%) and favorable OS after conversion (p = 0.015). In contrast, the BR classification had limited predictive value in patients with BCLC-B HCC. Notably, downstaging from BR1 to resectable status was more common than from BR2, suggesting higher conversion feasibility. CONCLUSIONS:Integrating BR classification with BCLC staging identified BCLC-C/BR1 patients as optimal candidates for conversion therapy after ATZ/BEV treatment. These findings support incorporating anatomical and oncological criteria into systemic strategies to enable curative interventions in advanced HCC.
AIM:In the GENESECT study, no significant gemcitabine (GEM) metabolism-related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab-paclitaxel, which has metabolic pathways different from GEM. The present study was a sub-analysis including only GEM monotherapy patients. METHODS:Of 159 patients analysed in the GENESECT study, only GEM-monotherapy patients were selected. The endpoints included carbohydrate antigen 19-9 (CA19-9) response (reduction ≥ 50% from the pretreatment level at 8 weeks), progression-free survival (PFS), and overall survival (OS) in relation to GPs. Analysed genes included those encoding GEM transporters and metabolic enzymes (SLC29A1, ABCC5, CDA, DCK, RRM1/2) and a tumour cell proliferation enzyme (COX-2). Screening and significance levels were set at 10% (univariable) and 5% (multivariable), respectively. RESULTS:Data for 50 patients were analysed. Genotype AA of ABCC5 1146A>G (rs7636910) showed a higher CA19-9 response rate than AG/GG (52.9% vs. 21.2%, p = 0.023) and remained significant in multivariable analysis (odds ratio: 6.255, p = 0.014). It also tended to be associated with longer PFS, but not significantly (hazard ratio [HR]: 0.464, p = 0.074). By contrast, although CA19-9 responses were not significantly associated with DCK -1205T>C (rs4694362), the TT/TC genotype was significantly associated with prolonged PFS compared with CC (median 127 vs. 48 days, p = 0.002), and this association remained significant in multivariable analysis (HR: 0.153, p = 0.028). No GPs were significantly associated with OS. CONCLUSION:ABCC5 and DCK might be related to the efficacy of GEM treatment, but further research is needed.
OBJECTIVES:A meta-analysis showed that serum folate concentrations, but not vitamin B12 concentrations, are lower in patients with ulcerative colitis compared to healthy controls. However, no epidemiological study has investigated the association between dietary intake of folate, vitamin B12, vitamin B6, vitamin B2, and vitamin B1 and the risk of ulcerative colitis. This study examines this association using data from a multicenter, hospital-based, case-control study. METHODS:The study included 384 cases of ulcerative colitis diagnosed within the past 3 years and 665 controls. Data were collected through a self-reported questionnaire. Dietary information was obtained using a 169-item semi-quantitative food frequency questionnaire. Adjustment was made for sex, age, pack-years of smoking, alcohol consumption, history of appendicitis, family history of ulcerative colitis, education level, and BMI. RESULTS:Higher dietary intakes of folate and vitamin B1 were independently associated with a decreased risk of ulcerative colitis after adjusting for confounding factors. The adjusted odds ratio for extreme quartiles was 0.60 [95% confidence interval (CI): 0.39 - 0.91, P for trend = 0.009) for folate and 0.54 (95% CI: 0.36 - 0.81, P for trend = 0.004) for vitamin B1. Dietary intake of vitamins B12, B6, or B2 was not independently associated with ulcerative colitis risk. CONCLUSION:This is the first study to demonstrate significant inverse relationships between dietary intake of folate and vitamin B1 and the risk of ulcerative colitis. Our results should be interpreted as exploratory and require validation through further, more focused studies.
BACKGROUND:Textbook outcome is a composite quality measure increasingly used in oncologic surgery but has not been applied to ulcerative colitis. Restorative proctocolectomy with IPAA is the standard surgical treatment for ulcerative colitis, yet a comprehensive assessment of surgical quality remains lacking. Pouchitis, the most common long-term complication after IPAA, significantly impairs quality of life and may lead to pouch failure. Linking perioperative success to long-term pouch function is therefore clinically relevant. OBJECTIVE:This study aimed to evaluate the feasibility and clinical relevance of textbook outcome as a perioperative quality measure and its association with long-term pouchitis after IPAA for ulcerative colitis. DESIGN:Nationwide multicenter retrospective cohort study. SETTING:Japan's collaborative ulcerative colitis surgery registry, including high-volume academic and affiliated hospitals. PATIENTS:A total of 1109 patients undergoing IPAA for ulcerative colitis between 2005 and 2019. MAIN OUTCOME MEASURES:Textbook outcome was defined as the absence of 90-day mortality, major complications (Clavien-Dindo grade III or higher), reoperation, readmission, and prolonged hospital stay. Logistic regression identified predictors of textbook outcome; Cox regression evaluated its association with pouchitis. RESULTS:Textbook outcome was achieved in 57% of patients. In multivariable logistic regression, male sex (OR 0.74, 95% CI, 0.57-0.95), higher preoperative albumin (OR 1.22, 95% CI, 1.01-1.47), and the presence of ulcerative colitis-associated neoplasia (OR 1.48, 95% CI, 1.03-2.14) were independently associated with achieving textbook outcome. Textbook outcome achievement increased significantly over time (OR per year 1.04, 95% CI, 1.01-1.07), coinciding with greater adoption of minimally invasive surgery. Failure to achieve textbook outcome was independently associated with higher pouchitis risk (HR 1.67, 95% CI, 1.12-2.49). LIMITATIONS:Retrospective design and registry-based data may involve unmeasured confounders. CONCLUSIONS:Textbook outcome is a feasible and clinically meaningful quality metric in ulcerative colitis IPAA surgery. Its achievement, improving over time with minimally invasive techniques, correlates with reduced pouchitis risk and may serve as a benchmark for surgical quality and outcomes in ulcerative colitis. See Video Abstract . RESULTADO TPICO TRAS UNA ANASTOMOSIS ILEOANAL CON BOLSA ILEAL PARA LA COLITIS ULCEROSA UN ESTUDIO MULTICNTRICO A NIVEL NACIONAL Y SUS IMPLICACIONES PARA LA CALIDAD DE VIDA A LARGO PLAZO:ANTECEDENTES:El resultado del libro de texto es una medida de calidad compuesta que se utiliza cada vez más en la cirugía oncológica, pero que no se ha aplicado a la colitis ulcerosa. La proctocolectomía restauradora con anastomosis ileoanal es el tratamiento quirúrgico estándar para la colitis ulcerosa, pero aún no se ha realizado una evaluación exhaustiva de la calidad quirúrgica. La pouchitis, la complicación a largo plazo más común tras la anastomosis ileoanal, deteriora significativamente la calidad de vida y puede provocar el fallo de la bolsa. Por lo tanto, relacionar el éxito perioperatorio con la función a largo plazo de la bolsa es clínicamente relevante.OBJETIVO:Evaluar la viabilidad y la relevancia clínica del resultado teórico como medida de calidad perioperatoria y su asociación con la pouchitis a largo plazo tras la anastomosis ileoanal para la colitis ulcerosa.DISEÑO:Estudio de cohorte retrospectivo multicéntrico a nivel nacional.ENTORNO:Registro colaborativo japonés de cirugía de colitis ulcerosa, que incluye hospitales académicos y afiliados de gran volumen.PACIENTES:Un total de 1109 pacientes sometidos a anastomosis ileoanal por colitis ulcerosa entre 2005 y 2019.PRINCIPALES MEDIDAS DE RESULTADO:El resultado teórico se definió como la ausencia de mortalidad a los 90 días, complicaciones graves (Clavien-Dindo ≥ III), reintervención, reingreso y estancia hospitalaria prolongada. La regresión logística identificó los predictores del resultado ideal; la regresión de Cox evaluó su asociación con la pouchitis.RESULTADOS:Se logró el resultado ideal en el 57 % de los pacientes. En la regresión logística multivariable, el sexo masculino (OR 0,74, IC del 95 %: 0,57-0,95), un nivel más alto de albúmina preoperatoria (OR 1,22, IC del 95 %: 1,01-1,47) y la presencia de neoplasia asociada a la CU (OR 1,48, IC del 95 %: 1,03-2,14) se asociaron de forma independiente con el logro del resultado ideal. El logro de resultados óptimos aumentó significativamente con el tiempo (OR por año 1,04, IC del 95 %: 1,01-1,07), coincidiendo con una mayor adopción de la cirugía mínimamente invasiva. El hecho de no lograr resultados óptimos se asoció de forma independiente con un mayor riesgo de pouchitis (HR 1,67, IC del 95 %: 1,12-2,49).LIMITACIONES:El diseño retrospectivo y los datos basados en registros pueden implicar factores de confusión no medidos.CONCLUSIONES:El resultado ideal es una medida de calidad viable y clínicamente significativa en la cirugía de anastomosis ileoanal con bolsa ileal para la colitis ulcerosa. Su consecución, que mejora con el tiempo gracias a las técnicas mínimamente invasivas, se correlaciona con un menor riesgo de pouchitis y puede servir como referencia para la calidad quirúrgica y los resultados en la colitis ulcerosa. (AI-generated translation ).